{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:30Z","timestamp":1772136390956,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84133-5","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T22:45:53Z","timestamp":1735857953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine\/thymidine phosphorylase inhibitor plus bevacizumab"],"prefix":"10.1038","volume":"15","author":[{"given":"Masatsune","family":"Shibutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kasashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunari","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84133_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager, G. W. et al. SUNLIGHT investigators. Trifluridine-tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl. J. Med. 388, 1657\u20131667 (2023).","journal-title":"N Engl. J. Med."},{"key":"84133_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer, P. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 412\u2013420 (2020).","journal-title":"Lancet Oncol."},{"key":"84133_CR3","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki, Y. et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 18, 1172\u20131181 (2017).","journal-title":"Lancet Oncol."},{"key":"84133_CR4","first-page":"449","volume":"27","author":"T Emura","year":"2005","unstructured":"Emura, T., Suzuki, N., Fujioka, A., Ohshimo, H. & Fukushima, M. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int. J. Oncol. 27, 449\u2013455 (2005).","journal-title":"Int. J. Oncol."},{"key":"84133_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1349-7006.2007.00477.x","volume":"98","author":"OH Temmink","year":"2007","unstructured":"Temmink, O. H., Emura, T., de Bruin, M., Fukushima, M. & Peters, G. J. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 98, 779\u2013789 (2007).","journal-title":"Cancer Sci."},{"key":"84133_CR6","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka, N. et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol. Rep. 32, 2319\u20132326 (2014).","journal-title":"Oncol. Rep."},{"key":"84133_CR7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto, K. et al. Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA. Int. J. Oncol. 46, 2327\u20132334 (2015).","journal-title":"Int. J. Oncol."},{"key":"84133_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jjco\/hyaa243","volume":"51","author":"T Yoshino","year":"2021","unstructured":"Yoshino, T. et al. Post-marketing surveillance study of trifluridine\/tipiracil in patients with metastatic colorectal cancer. Jpn J. Clin. Oncol. 51, 700\u2013706 (2021).","journal-title":"Jpn J. Clin. Oncol."},{"key":"84133_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CAD.0000000000000554","volume":"29","author":"A Falcone","year":"2018","unstructured":"Falcone, A. et al. Integrated safety summary for trifluridine\/tipiracil (TAS-102). Anticancer Drugs. 29, 89\u201396 (2018).","journal-title":"Anticancer Drugs"},{"key":"84133_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s10147-023-02389-9","volume":"28","author":"N Yoshida","year":"2023","unstructured":"Yoshida, N. et al. Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. Int. J. Clin. Oncol. 28, 1378\u20131387 (2023).","journal-title":"Int. J. Clin. Oncol."},{"key":"84133_CR11","doi-asserted-by":"publisher","first-page":"17931","DOI":"10.1038\/s41598-023-45244-7","volume":"13","author":"M Shiroyama","year":"2023","unstructured":"Shiroyama, M. et al. Renal impairment as a risk factor for trifluridine\/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study. Sci. Rep. 13, 17931 (2023).","journal-title":"Sci. Rep."},{"key":"84133_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2017.01.003","volume":"16","author":"JJ Lee","year":"2017","unstructured":"Lee, J. J. & Chu, E. Adherence, dosing, and managing toxicities with Trifluridine\/Tipiracil (TAS-102). Clin. Colorectal Cancer. 16, 85\u201392 (2017).","journal-title":"Clin. Colorectal Cancer"},{"key":"84133_CR13","unstructured":"Japanese Society of Nephrology. Guideline, Evidence-based Practice Guideline for the Treatment of CKD. [cited 2024 May 2]. Available from https:\/\/jsn.or.jp\/en\/guideline\/guideline.php"},{"key":"84133_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"84133_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"84133_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl. J. Med. 372, 1909\u20131919 (2015).","journal-title":"N Engl. J. Med."},{"key":"84133_CR17","doi-asserted-by":"crossref","unstructured":"Moriwaki, T. et al. Propensity Score Analysis of Regorafenib Versus Trifluridine\/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist. 23, 7\u201315 (2018).","DOI":"10.1634\/theoncologist.2017-0275"},{"key":"84133_CR18","doi-asserted-by":"publisher","first-page":"175883592110091","DOI":"10.1177\/17588359211009143","volume":"13","author":"K Chida","year":"2021","unstructured":"Chida, K. et al. Efficacy and safety of trifluridine\/tipiracil plus bevacizumab and trifluridine\/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Ther. Adv. Med. Oncol. 13, 17588359211009143 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"84133_CR19","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0541","volume":"25","author":"H Fujii","year":"2020","unstructured":"Fujii, H. et al. Bevacizumab in Combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal Cancer: a retrospective study. Oncologist 25, e469\u2013e476 (2020).","journal-title":"Oncologist"},{"key":"84133_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-019-6475-6","volume":"19","author":"D Kotani","year":"2019","unstructured":"Kotani, D. et al. Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. 19, 1253 (2019).","journal-title":"BMC Cancer"},{"key":"84133_CR21","unstructured":"Trifluridine\/tipiracil. (Lonsurf) Prescribing Information Guide (Taiho Pharmaceutical Co., Ltd., 2024). (in Japanese)."},{"key":"84133_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.resinv.2016.05.007","volume":"54","author":"T Kikuchi","year":"2016","unstructured":"Kikuchi, T. et al. Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer. Respir Investig. 54, 479\u2013483 (2016).","journal-title":"Respir Investig"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84133-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84133-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:03:06Z","timestamp":1735948986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84133-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84133"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84133-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4957923\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"553"}}